Mar 10, 2020
Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform. Gil explains how cell therapies work by providing multi-dimensional solutions and regenerative medicine therapies differ from traditional pharmaceuticals or biologics designed to do one very specific thing. He also talks about how MultiStem has shown dramatic impact on stroke victims and on acute respiratory distress syndrome and inflammation in the lungs and their related work with lung transplant centers.
@Athersys #regenerativemedicine #ARDS